Elicio Therapeutics
Focus: Elicio Therapeutics is a Boston-based biotechnology company focused on HPV-induced cancer treatments, currently in early-stage clinical development with a pipeline centered on immunotherapy approaches. The company is public (NASDAQ: ELTX) but remains pre-revenue with minimal commercial infrastructure.
Profile data last refreshed 6h ago · AI intelligence enriched 1mo ago
Open Jobs
1
Should You Work at Elicio Therapeutics?
AI assessmentCareer-building opportunity if you seek early-stage oncology drug development and can tolerate execution risk; proceed with caution given market delisting and severely constrained hiring.
Why Work Here
- Focused therapeutic area (HPV-induced cancers) offers deep scientific specialization and clear clinical validation pathway in high-unmet-need oncology.
Data completeness
4/9 — Basic
Company HealthSolid
Pipeline
Early-stage
3 total
LOE Risk
Protected
No near-term cliffs
Hiring
Stable
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
ELI-002 7P
Pancreatic Ductal AdenocarcinomaClinical Trials (1)
NCT07083479Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal Adenocarcinoma
N/AHelp build intelligence for Elicio Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.